Calcium Hydroxide
drugOn this page
Also known as Calcarea causticaCalcium hydroxide (ca(oh)2)Calcium hydroxide solutionE-526INS NO.526INS-526Lime hydrateLime waterSlaked limeSlaked-lime
Summary
Calcium Hydroxide (CHEMBL2106388) is an approved small-molecule astringent; indicated across 4 conditions including periodontitis and exposure, dental pulp.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 4 conditions
- Clinical trials: 54
- Chemistry: 74.09 Da · CaH2O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2106388 |
| Name | Calcium Hydroxide |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 6093208 |
| ChEBI | CHEBI:31341 |
| Molecular formula | CaH2O2 |
| Molecular weight | 74.09 |
| InChIKey | AXCZMVOFGPJBDE-UHFFFAOYSA-L |
SMILES: [OH-].[OH-].[Ca+2]
IUPAC name: calcium dihydroxide
Pharmacological roles (ChEBI): astringent.
Also known as: Calcarea caustica, Calcium hydroxide, Calcium hydroxide (ca(oh)2), Calcium hydroxide solution, E-526, INS NO.526, INS-526, Lime hydrate, Lime water, Slaked lime, Slaked-lime, CALCIUM HYDROXIDE
Patent coverage: 154,786 distinct patent families (347,829 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| periodontitis | 3 | MONDO:0005076 | EFO:0000649 |
| exposure, dental pulp | 2 | MONDO:0020812 | EFO:1001782 |
| dental caries | 1 | MONDO:0005276 | EFO:0003819 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 54.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 33 |
| PHASE4 | 5 |
| PHASE2/PHASE3 | 5 |
| PHASE3 | 4 |
| EARLY_PHASE1 | 4 |
| PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06683833 | PHASE4 | RECRUITING | Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth |
| NCT07388888 | PHASE4 | NOT_YET_RECRUITING | Antibacterial Effect of Two Different Intracanal Medicaments and Their Effect on Post-operative Pain |
| NCT03084601 | PHASE4 | COMPLETED | Evaluation of Postoperative Pain After Using 3MIX-TATIN Versus Calcium Hydroxide Iodoform Paste In Necrotic Primary Molars Treated by Lesion Sterilization and Tissue Repair Therapy |
| NCT03692286 | PHASE4 | COMPLETED | Assessment of Postoperative Pain After Using Various Intracanal Medication in Patients With Necrotic Pulp |
| NCT06807320 | PHASE4 | COMPLETED | COMPARISON of MINERAL TRIOXIDE AGGREGATE and CALCIUM HYDROXIDE AS INDIRECT PULP CAPPING AGENTS in PRIMARY MOLARS |
| NCT06196515 | PHASE2/PHASE3 | RECRUITING | Anti-bacterial Potential of Nano Calcium Hydroxide as an Intracanal Medication |
| NCT06207253 | PHASE2/PHASE3 | RECRUITING | The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament |
| NCT06453304 | PHASE2/PHASE3 | RECRUITING | Effectiveness of Glycyrrhizin as Intracanal Medication in Root Canal Disinfection and Inflammatory Cytokines |
| NCT06466538 | PHASE2/PHASE3 | RECRUITING | InvestigateClinically the Effectiveness of Boswellia Based Intracanal Medication Compared to Calcium Hydroxide Ca(OH)2 and Ledermix on the Levels of Bacteria and Inflammatory Cytokines in Root Canals and Periradicular Tissues of Teeth With Apical Periodontitis |
| NCT00472173 | PHASE3 | COMPLETED | Assessment of a New Apexification Method for Patients Presenting a Non Vital Immature Tooth |
| NCT02492841 | PHASE2/PHASE3 | COMPLETED | Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent Teeth |
| NCT03700788 | PHASE3 | UNKNOWN | 2% Chlorhexidine (CHX) vs CaOH2 (CH) Calcium Hydroxide Paste as an Intracanal Medicament |
| NCT03723980 | PHASE3 | COMPLETED | Role of Propolis Paste in Preventing Pain After Root Canal Treatment. |
| NCT05928858 | PHASE3 | UNKNOWN | Clinical And Radiographic Evaluation Of Premixed Bio-ceramic MTA In Indirect Pulp Capping Of Young Permanent Molars |
| NCT01730287 | PHASE2 | UNKNOWN | Effect Of Different Lining Materials in Stepwise Excavation |
| NCT02824601 | PHASE2 | COMPLETED | Photodynamic Therapy in Endodontic Treatment |
| NCT05266859 | PHASE2 | COMPLETED | Efficacy of PRF and MTA as Compared to Calcium Hydroxide for Pulpotomy in Human Irreversibly Inflamed Permanent Teeth |
| NCT07603934 | EARLY_PHASE1 | RECRUITING | The Effect of Different Intra-canal Medications on Postoperative Pain |
| NCT03209115 | EARLY_PHASE1 | UNKNOWN | Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicaments in Retreatment Cases |
| NCT05666089 | EARLY_PHASE1 | UNKNOWN | Effect of N-acetylcysteine Versus Calcium Hydroxide Used as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Levels of MMP -9 in Periapical Fluids in Patients With Necrotic Pulp |
| NCT05687760 | EARLY_PHASE1 | UNKNOWN | Effect of Bromelain Versus Calcium Hydroxide as an Intracanal Medication on the Intensity of Postoperative Pain and Bacterial Load Reduction in Necrotic Single Rooted Lower Premolars |
| NCT06755502 | Not specified | NOT_YET_RECRUITING | Garlic Oil As Root Filling Material in Primary Molars |
| NCT07183514 | Not specified | NOT_YET_RECRUITING | A Study Comparing Eggshell Based and Gold Standard Materials to Heal Deep Tooth Damage in Adult Molars |
| NCT07194837 | Not specified | RECRUITING | The Efficiency of 810 nm Diode Laser on Periapical Healing After Root Canal Retreatment |
| NCT07239739 | Not specified | NOT_YET_RECRUITING | Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment |
| NCT07252258 | Not specified | ACTIVE_NOT_RECRUITING | Comparison of Frequency of Calcium Hydroxide Mixed With 0.2% Chlorhexidine Versus Saline as Intracanal Medicament in Periapical Periodontitis-A Randomized Controlled Trial |
| NCT07327996 | Not specified | ACTIVE_NOT_RECRUITING | Evaluation of Pain Relief and Bacterial Reduction After Using Calcium Hydroxide With Mesoporous Silica Nanoparticles as an Intracanal Medicament in Necrotic Mandibular Molars: A Randomized Controlled Clinical Trial |
| NCT07371416 | Not specified | ACTIVE_NOT_RECRUITING | Regenerative Root Canal Treatment of Immature Teeth Using Omega-3 Fatty Acids |
| NCT07495605 | Not specified | NOT_YET_RECRUITING | Effect of 1% Melatonin Gel Versus Calcium Hydroxide as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp. |
| NCT07578311 | Not specified | NOT_YET_RECRUITING | Effect of a Herbal Intracanal Medication On Postoperative Pain And Flare up Incidence In Non Surgical Root Canal Retreatment |
| NCT07585721 | Not specified | NOT_YET_RECRUITING | Postoperative Pain and Substance P Levels After Bioceramic vs Calcium Hydroxide Intracanal Medicaments in Symptomatic Apical Periodontitis |
| NCT00812877 | Not specified | COMPLETED | Pulp Capping With Two Different Agents |
| NCT02487329 | Not specified | COMPLETED | The Effect of Laser Combined With Pulp-capping Agents on Direct Pulp Capping |
| NCT03032978 | Not specified | COMPLETED | Calcium Silicate Versus Calcium Hydroxide in Two-step Indirect Pulp Treatment |
| NCT03336970 | Not specified | COMPLETED | Efficacy of Chlorhexidine as a Final Irrigant in Single-visit Root Canal Treatment |
| NCT03403985 | Not specified | UNKNOWN | Long-term Evaluation of Direct Pulp Capping |
| NCT03606681 | Not specified | COMPLETED | Clinical and Radiographic Evaluation of Indirect Pulp Capping in Primary and Permanent Teeth With Different Materials |
| NCT03631277 | Not specified | COMPLETED | Indirect Pulp Treatment of Young Permanent Molars Using Photo-Activated Oral Disinfection Versus Calcium Hydroxide |
| NCT03724266 | Not specified | UNKNOWN | Effect of Using Nanochitosan Versus Calcium Hydroxide as Disinfectant on Pain and Apical Bone Healing |
| NCT03855501 | Not specified | COMPLETED | Apexification Treatment With MTA(Mineral Trioxide Aggregate) and Ca(OH)2 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: periodontitis